Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma
MUNICH--(BUSINESS WIRE)--EMA grants orphan drug designation for Isarna’s ISTH0036, a LNA-modified antisense oligonucleotide targeting TGF-β2, for the prevention of scarring post trabeculectomy in glaucoma.
